Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Squamous Cell Carcinoma

STOCKHOLM, Dec. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC).